Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

XTRA:BAYN
XTRA:BAYNPharmaceuticals

Assessing Bayer (XTRA:BAYN) Valuation After Positive OCEANIC STROKE Trial Milestone

Bayer (XTRA:BAYN) is back in focus after confirming that its large Phase III OCEANIC-STROKE trial of asundexian met primary efficacy and safety endpoints, with full results set for presentation at the 2026 International Stroke Conference. See our latest analysis for Bayer. Those OCEANIC STROKE headlines arrive after a sharp shift in sentiment, with Bayer’s 30 day share price return of 18.21% and 90 day share price return of 62.34%, while the 1 year total shareholder return of 101.10%...